Mok, A., Haldar, S., Lee, J
However, DPP-4 inhibitors (such as sitagliptin or linagliptin) should be discontinued when initiating semaglutide, as both drug classes work through incretin pathways, and combined use offers no additional glycemic benefit while potentially increasing adverse effects
Introduced to the market by Novo Nordisk in 2026, oral semaglutide is the first oral GLP-1 receptor agonist approved specifically for weight management
The Showdown: Shea Butter vs
Weight management (and the treatment of weight-related comorbidities) is not one-size-fits-all
Patients are encouraged to only acquire authentic Novo Nordisk Ozempic (semaglutide) injection 1 mg through state-licensed pharmacies and to check the product for any signs of counterfeiting before using